Danaher (NYSE:DHR) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Tuesday.

According to Zacks, “Over the past six months, Danaher has outperformed the industry average. We are optimistic about the company’s core revenue and earnings growth, on the back of improving order trends and its operating culture, DBS. Going forward, the company expects the biopharma business to be a major growth driver. Its recent acquisitions – Pall and Cepheid – are proving to be strong profit churners, and will boost top-line growth as they become a part of the company’s core revenues. However, on the flip side, sluggish economic conditions across key operating regions and unfavorable currency translations pose as threats. Especially, slowdown in the company’s academic business in Europe and prolonged sluggishness in the Dental business might restrict growth, going forward. Moreover, weakness in industrial markets and stiff competition may also hurt the company's financials.”

A number of other research analysts also recently issued reports on the company. J P Morgan Chase & Co reiterated an “overweight” rating and set a $95.00 price objective on shares of Danaher in a research note on Friday, September 8th. Goldman Sachs Group reiterated a “neutral” rating and set a $83.00 price objective on shares of Danaher in a research note on Tuesday, September 26th. Cowen reiterated a “buy” rating and set a $90.00 price objective on shares of Danaher in a research note on Wednesday, October 4th. Morgan Stanley reiterated an “overweight” rating and set a $95.00 price objective (up from $86.00) on shares of Danaher in a research note on Friday, October 6th. Finally, Credit Suisse Group boosted their price objective on Danaher from $93.00 to $96.00 and gave the company an “outperform” rating in a research note on Friday, October 20th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. Danaher has an average rating of “Buy” and an average target price of $94.38.

Danaher (DHR) traded up $0.36 during midday trading on Tuesday, hitting $94.36. 2,960,600 shares of the stock traded hands, compared to its average volume of 2,628,380. Danaher has a 12-month low of $77.66 and a 12-month high of $94.84. The stock has a market cap of $65,386.89, a price-to-earnings ratio of 24.17, a P/E/G ratio of 2.24 and a beta of 1.02. The company has a quick ratio of 1.00, a current ratio of 1.43 and a debt-to-equity ratio of 0.42.

Danaher (NYSE:DHR) last released its quarterly earnings results on Thursday, October 19th. The conglomerate reported $1.00 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.95 by $0.05. Danaher had a net margin of 13.36% and a return on equity of 11.29%. The firm had revenue of $4.53 billion during the quarter, compared to analyst estimates of $4.47 billion. During the same quarter in the prior year, the firm earned $0.87 EPS. The business’s revenue for the quarter was up 9.6% compared to the same quarter last year. analysts forecast that Danaher will post 3.99 EPS for the current fiscal year.

In other Danaher news, SVP Daniel Raskas sold 37,870 shares of the company’s stock in a transaction that occurred on Thursday, November 16th. The stock was sold at an average price of $93.33, for a total value of $3,534,407.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Robert S. Lutz sold 11,189 shares of the company’s stock in a transaction that occurred on Monday, October 23rd. The stock was sold at an average price of $91.66, for a total value of $1,025,583.74. Following the completion of the transaction, the chief accounting officer now owns 18,314 shares of the company’s stock, valued at $1,678,661.24. The disclosure for this sale can be found here. Insiders sold a total of 273,810 shares of company stock valued at $25,218,813 over the last 90 days. 12.20% of the stock is currently owned by corporate insiders.

Hedge funds have recently bought and sold shares of the business. ETRADE Capital Management LLC raised its holdings in shares of Danaher by 5.1% during the 2nd quarter. ETRADE Capital Management LLC now owns 19,075 shares of the conglomerate’s stock worth $1,610,000 after acquiring an additional 917 shares in the last quarter. Honeywell International Inc. purchased a new stake in shares of Danaher during the 2nd quarter worth approximately $25,317,000. Roundview Capital LLC raised its holdings in shares of Danaher by 2.0% during the 2nd quarter. Roundview Capital LLC now owns 25,674 shares of the conglomerate’s stock worth $2,167,000 after acquiring an additional 502 shares in the last quarter. Eastern Bank raised its holdings in shares of Danaher by 4,291.1% during the 2nd quarter. Eastern Bank now owns 128,001 shares of the conglomerate’s stock worth $10,802,000 after acquiring an additional 125,086 shares in the last quarter. Finally, Perkins Coie Trust Co raised its holdings in shares of Danaher by 2.0% during the 2nd quarter. Perkins Coie Trust Co now owns 29,431 shares of the conglomerate’s stock worth $2,484,000 after acquiring an additional 586 shares in the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This article was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/12/19/zacks-investment-research-lowers-danaher-dhr-to-hold.html.

Danaher Company Profile

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Get a free copy of the Zacks research report on Danaher (DHR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.